Case Study: Assessing Migraine Compound Efficacy With Real-time in Vivo Vascular Imaging
Coming from inscopix.com?
You’re in the right place! Inscopix Miniscopes are moving to Bruker.com; in the coming weeks, you’ll see more miniscope details and resources consolidated here.
Same quality, same products, same team – just a smoother, more unified experience.
Discover a novel behavioral method for assessing drug efficacy
This technical note discusses a novel approach allowing real-time in vivo blood vessel imaging from meningeal, superficial, and deep brain areas in freely moving animals.
Readers can expect to learn more about:
- Inscopix neuroimaging tools for studying migraine-related blood flow changes in freely-behaving animal models
- Vascular mechanisms underlying migraine, including how blood flow dynamics correlate with neural activity
- Inscopix miniscope experimental design and methodology for drug efficacy screening
- Other advantages of using Inscopix technology for real-time, high-resolution imaging in neuroscience applications.
The time is now for a more predictive approach to preclinical neurotherapeutic drug development
The Need
To discover the next generation of more effective therapies, neuroscientists need much better efficacy and side-effect models that transcend the well-established shortcomings of traditional behavioral methods.
The Approach
The Inscopix platform’s new approach now allows real-time in-vivo blood vessel imaging from meningeal, superficial, and deep brain areas in freely moving animals, enabling longitudinal red blood cell velocity and vessel diameter measurement. Our imaging technologies directly visualize the complexities of the living, behaving brain – opening up completely new, ultra-powerful, and highly relevant data types.
Key Benefits
- Detect acute drug response
- Measure adaptive response to chronic pharmacology
- Longitudinally characterize the progression of migraine models
The Application
Our platform is primarily used in mice and rats, but has also been applied in other preclinical species including non-hu-man primates. Our technology readily captures powerful longitudinal information continuously over hours to define an acute drug activity response, to imaging across weeks or months to follow progression of disease pathology or adap-tive responses to chronic pharmacology. Inscopix has re-cently developed an assay for efficacy screening of novel mi-graine therapies, providing sensitive and quantitative time courses of vasodilation and vasoconstriction in response to migraine-inducer compounds with and without treatment.
Transform your neuroscience drug development
Inscopix is proud to partner with hundreds of laboratories worldwide to bring new and valuable insights to their research. We collaborate with a number of pharma and biotech companies in several ways, including supporting their internal use of Inscopix systems and analytics. We also conduct collaborative contracted research studies in our labs in Mountain View, CA. Contact us to start the conversation.
